Jawbone Cavitation Expressed RANTES/CCL5: Case Studies Linking Silent Inflammation in the Jawbone with Epistemology of Breast Cancer

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2021 Apr 16

PMID 33859496

Citations 4

Authors

Johann Lechner

Tilman Schulz

Beatrice Lejeune

Volker von Baehr

Affiliations

Soon will be listed here.

Abstract

Background: The role of signaling pathways as part of the cell-cell communication within cancer progression becomes a crucial area. Chemokine RANTES (regulated upon activation, normal T-cell expressed and secreted), also known as the chemokine C-C motif ligand 5 (CCL5) (R/C), is a protein on which cancer research focus due to its link with aggressive cancer development.

Objective: Research on fatty-degenerative osteonecrosis in jawbone (FDOJ) shows striking overexpression of R/C in these areas. Here we try to elucidate a potential link between jawbone-derived R/C and breast cancer (BC) and compare these findings by immunohistochemical staining.

Methods: Thirty-nine FDOJ samples extracted from 39 BC patients and samples from 19 healthy control were analyzed for R/C expression using bead-based Luminex analysis. R/C levels from 5 BC patients were measured in serum before and after FDOJ surgery. Bone density, histology, R/C expression, and immunohistochemistry were analysed in 4 clinical case studies. The R/C staining of two FDOJ BC patients is compared with the immunohistochemical staining of BC cell preparations.

Results: A high overexpression of R/C was seen in all FDOJ samples. R/C levels in serum were statistically downregulated after FDOJ surgery (p=0.0241).

Discussion: R/C induced "silent inflammation" in BC is widely discussed in scientific papers along with R/C triggering of different signaling pathways, which might be a key point in the development of BC.

Conclusion: Hypothesis that FDOJ may serve as a trigger of BC progression through R/C overexpression was set by the authors, who thus inspire clinicians to make aware of FDOJ throughout the dental and medical community in BC cases.

Citing Articles

Fatty Degenerative Osteonecrosis of the Jaw: Bridging Molecular Insights and Clinical Practice-A Scoping Review.

Dominiak M, Niemczyk W, Pitulaj A, Swienc W, Matys J Int J Mol Sci. 2025; 26(5).

PMID: 40076479 PMC: 11899097. DOI: 10.3390/ijms26051853.

Osteoimmune Interaction and TH-1/TH-2 Ratio in Jawbone Marrow Defects: An Underestimated Association - Original Research.

Lechner J, von Baehr V, Notter F, Schick F Biologics. 2024; 18:147-161.

PMID: 38859969 PMC: 11164205. DOI: 10.2147/BTT.S448587.

Exploring the Potential of Micro-Immunotherapy in the Treatment of Periodontitis.

Ferra-Canellas M, Garcia-Sureda L Life (Basel). 2024; 14(5).

PMID: 38792574 PMC: 11122531. DOI: 10.3390/life14050552.

Osseointegration and osteoimmunology in implantology: assessment of the immune sustainability of dental implants using advanced sonographic diagnostics: research and case reports.

Lechner J, von Baehr V, Notter F, Schick F J Int Med Res. 2024; 52(1):3000605231224161.

PMID: 38259068 PMC: 10807457. DOI: 10.1177/03000605231224161.

Reduction of Inflammatory RANTES/CCL5 Serum Levels by Surgery in Patients with Bone Marrow Defects of the Jawbone.

Diederich J, Schwagten H, Biltgen G, Lechner J, Muller K Clin Cosmet Investig Dent. 2023; 15:181-188.

PMID: 37705670 PMC: 10496923. DOI: 10.2147/CCIDE.S417783.

References

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Chaitchik S . Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999; 59(18):4681-7. View

Khalid A, Wolfram J, Ferrari I, Mu C, Mai J, Yang Z . Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer. Mini Rev Med Chem. 2015; 15(13):1063-72. PMC: 4968951. DOI: 10.2174/138955751513150923094709. View

White G, Iqbal A, Greaves D . CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013; 65(1):47-89. DOI: 10.1124/pr.111.005074. View

Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai E, Azenshtein E . The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 2006; 12(15):4474-80. DOI: 10.1158/1078-0432.CCR-06-0074. View

Lechner J, von Baehr V . RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?. Int J Gen Med. 2013; 6:277-90. PMC: 3636973. DOI: 10.2147/IJGM.S43852. View

Romagnani S . Cytokines and chemoattractants in allergic inflammation. Mol Immunol. 2002; 38(12-13):881-5. DOI: 10.1016/s0161-5890(02)00013-5. View

Chaturvedi P, Gilkes D, Takano N, Semenza G . Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci U S A. 2014; 111(20):E2120-9. PMC: 4034192. DOI: 10.1073/pnas.1406655111. View

Nicolini A, Carpi A, Rossi G . Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006; 17(5):325-37. DOI: 10.1016/j.cytogfr.2006.07.002. View

Kohlmeier J, Miller S, Smith J, Lu B, Gerard C, Cookenham T . The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity. 2008; 29(1):101-13. PMC: 2519120. DOI: 10.1016/j.immuni.2008.05.011. View

10.

Vaday G, Peehl D, Kadam P, Lawrence D . Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2005; 66(2):124-34. DOI: 10.1002/pros.20306. View

11.

Lechner J, Schuett S, von Baehr V . Aseptic-avascular osteonecrosis: local "silent inflammation" in the jawbone and RANTES/CCL5 overexpression. Clin Cosmet Investig Dent. 2017; 9:99-109. PMC: 5687454. DOI: 10.2147/CCIDE.S149545. View

12.

Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R . Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004; 10(20):6789-95. DOI: 10.1158/1078-0432.CCR-04-0306. View

13.

Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A . A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 2004; 445(3):236-47. DOI: 10.1007/s00428-004-1053-x. View

14.

Bussolino F, Mantovani A, Persico G . Molecular mechanisms of blood vessel formation. Trends Biochem Sci. 1997; 22(7):251-6. DOI: 10.1016/s0968-0004(97)01074-8. View

15.

Tomiyama K, Murase N, Stolz D, Toyokawa H, ODonnell D, Smith D . Characterization of transplanted green fluorescent protein+ bone marrow cells into adipose tissue. Stem Cells. 2007; 26(2):330-8. PMC: 2268622. DOI: 10.1634/stemcells.2007-0567. View

16.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

17.

Nieman K, Romero I, Van Houten B, Lengyel E . Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013; 1831(10):1533-41. PMC: 3742583. DOI: 10.1016/j.bbalip.2013.02.010. View

18.

Andarawewa K, Motrescu E, Chenard M, Gansmuller A, Stoll I, Tomasetto C . Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res. 2005; 65(23):10862-71. DOI: 10.1158/0008-5472.CAN-05-1231. View

19.

Velasco-Velazquez M, Pestell R . The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology. 2013; 2(4):e23660. PMC: 3654591. DOI: 10.4161/onci.23660. View

20.

Liu S, Dontu G, Wicha M . Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005; 7(3):86-95. PMC: 1143566. DOI: 10.1186/bcr1021. View